摘要
评价CVM_(26)-CAP方案交替使用治疗小细胞肺癌(SCLC)的近期疗效.方法 本组共包括我院1995年6月—1998年6月收治的可评价疗效的sclc48例.男38例,女10例.年龄28～70岁.全部病例均经细胞学及/或病理学证实.局限期(LD)37例,广泛期(ED)11例.均为初治病例,有可测量的临床和X线观察指标.可评价近期疗效.治疗采用CVM_(26)CAP两方案交替使用,4周期后评价疗效.结果 48例中.完全缓解6例(12.5%),部分缓解36例(75.0%),稳定4例(8.3%),进展2例(4.2%),总有效率为87.5%(42/48).主要毒性为消化道反应和骨髓抑制,临床观察病人可以耐受.结论 本方案有效率较高,可以推荐作为SCLC化疗的首选方案.
Objective To evaluate the response rate of small cell lung cancer (SCLC) treated with CVM26 -CAP alternating regimen. Methods Fourty - eight evaluable patients with SCLC in our hospital from Jun. 1995 to Jun. 1998 were analysed. There were 38 men and 10 women. The age ranged from 26 to 70 years. All were proven by pathology and/or cytology. Of them,37 patients had linited disease (LD) and 11, extensive disease (ED). They all did not receive previous treatment and had a measurable mass. CVM26-CAP alternating chemotherapy were given four cycles. Results The total response rate was 87. 5%(42/48) including complete remission in 6 cases(12. 5%), partial remission in 36 cases (75. 0%), stability in 4 cases (8. 3%) and progression in 2 cases (4- 2% ). The main toxicity observed was nausea, vomiting and bone marrow supression, but was tolerated by the patients. Conclusion CVM26-CAP regimen can be recommended as the first of choice in treating SCLC.
出处
《淮海医药》
1999年第3期17-18,共2页
Journal of Huaihai Medicine
